Figure 2.
Time course of DLQI that was significantly in favor of omalizumab treatment in the atopic dermatitis/asthma group (P < 0.05: 2 months, 3 months, 6 months and 12 months vs. baseline).
Time course of DLQI that was significantly in favor of omalizumab treatment in the atopic dermatitis/asthma group (P < 0.05: 2 months, 3 months, 6 months and 12 months vs. baseline).